Manganese porphyrin given at symptom onset markedly extends survival of ALS mice
Authors:
- 27 July 2005
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 58 (2) , 258-265
Abstract
Mice that overexpress the human Cu,Zn superoxide dismutase‐1 mutant G93A develop a delayed and progressive motor neuron disease similar to human amyotrophic lateral sclerosis (ALS). Most current studies of therapeutics in these mice to date have involved administration of agents long before onset of symptoms, which cannot currently be accomplished in human ALS patients. We examined the effects of the manganese porphyrin AEOL 10150 (manganese [III] tetrakis[N‐N′‐diethylimidazolium‐2‐yl]porphyrin) given at symptom onset and found, in three separate studies, that it extended the survival after onset up to 3.0‐fold. Immunohistochemical analysis of spinal cord for SMI‐32, an abundant protein in motor neurons, indicated better preservation of motor neuron architecture, less astrogliosis (glial fibrillary acidic protein), and markedly less nitrotyrosine and malondialdehyde in porphyrin‐treated spinal cords relative to vehicle‐treated mice. These results show that the catalytic antioxidant AEOL 10150 provides a pronounced therapeutic benefit with onset administration and is, therefore, a promising agent for the treatment of ALS. Ann Neurol 2005;58:258–265Keywords
This publication has 27 references indexed in Scilit:
- MRI detects early hindlimb muscle atrophy in Gly93Ala superoxide dismutase‐1 (G93A SOD1) transgenic mice, an animal model of familial amyotrophic lateral sclerosisNMR in Biomedicine, 2004
- Reactions of Manganese Porphyrins with Peroxynitrite and Carbonate Radical AnionJournal of Biological Chemistry, 2003
- Assessing disease onset and progression in the SOD1 mouse model of ALSNeuroReport, 2003
- Assessing disease onset and progression in the SOD1 mouse model of ALSNeuroReport, 2003
- Of mice and men: Reconciling preclinical ALS mouse studies and human clinical trialsAnnals of Neurology, 2003
- Therapeutic developments in the treatment of amyotrophic lateral sclerosisExpert Opinion on Investigational Drugs, 2002
- Increased 3‐nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutationAnnals of Neurology, 1997
- Brain superoxide dismutase, catalase, and glutathione peroxidase activities in amyotrophic lateral sclerosisAnnals of Neurology, 1996
- Age-Dependent Penetrance of Disease in a Transgenic Mouse Model of Familial Amyotrophic Lateral SclerosisMolecular and Cellular Neuroscience, 1995
- Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.Journal of Histochemistry & Cytochemistry, 1981